...
首页> 外文期刊>BMC Cancer >Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery
【24h】

Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery

机译:腺癌和腺瘤性癌患者在激进手术后的FOPPATIACE IA-IIA宫颈癌患者中的比较

获取原文
           

摘要

BACKGROUND:To compare adenocarcinoma (AC) and adenosquamous carcinoma (ASC) prognoses in patients with FIGO stage IB-IIA cervical cancer who underwent radical hysterectomy.METHODS:We performed a retrospective analysis of 240 patients with AC and 130 patients with ASC. Kaplan-Meier curves, Cox regression models, and log-rank tests were used for statistical analysis.RESULTS:Patients with ASC had higher frequencies of lymphovascular space invasion (LVSI) and serum squamous cell carcinoma antigen (SCC-Ag)??5?ng/ml (p?=?0.049 and p?=?0.013, respectively); moreover, they were much older (P?=?0.029) than patients with AC. There were no clinically significant differences in overall survival (OS) between the groups. When stratified into three risk groups based on clinicopathological features, survival outcomes did not differ between patients with AC and those with ASC in any risk group. Multivariate analysis showed that lymph node metastasis (LNM) was an independent risk factor for recurrence-free survival (RFS) and OS in patients with AC and in patients with ASC. Carcinoembryonic antigen (CEA)??5?ng/ml and SCC-Ag??5?ng/ml were independent predictors of RFS and OS in patients with AC. In addition, among those stratified as intermediate-risk, patients with ASC who received concurrent chemoradiotherapy (CCRT) had significantly better RFS and OS (P?=?0.036 and P?=?0.047, respectively).CONCLUSIONS:We did not find evidence to suggest that AC and ASC subtypes of cervical cancer were associated with different survival outcomes. CCRT is beneficial for survival in intermediate-risk patients with ASC, but not in those with AC. Serum tumour markers can assist in evaluating prognosis and in providing additional information for patient-tailored therapy for cervical AC.
机译:背景:对比较腺癌(AC)和腺细胞正症癌(ASC)患者在近期术后宫颈癌的患者中进行了处理,他们接受了自由基的子宫切除术。方法:我们对240例AC和130名ASC患者进行了回顾性分析。 Kaplan-Meier曲线,Cox回归模型和日志秩检验用于统计分析。结果:ASC的患者具有较高频率的淋巴血管空间入侵(LVSI)和血清鳞状细胞癌抗原(SCC-AG)?> 5 ?ng / ml(p?= 0.049和p?=?0.013);此外,它们比AC的患者更老了(P?= 0.029)。组之间的整体存活(OS)没有临床上显着差异。当基于临床病理特征分为三个风险群时,AC患者与任何风险组中ASC的患者之间的存活结果没有差异。多变量分析表明,淋巴结转移(LNM)是AC和ASC患者的无复发存活(RFS)和OS的独立危险因素。癌胚抗原(CEA)?> 5?Ng / ml和SCC-Ag?> 5?Ng / ml是AC患者的RFS和OS的独立预测因子。此外,在分层的那些中,ASC的患者接受并发的化学疗法(CCRT)具有明显更好的RFS和OS(P?= 0.036和P?= 0.047)。结论:我们没有找到证据建议宫颈癌的AC和ASC亚型与不同的存活结果有关。 CCRT有益于中毒患者的存活,但不在AC的患者中。血清肿瘤标志物可以有助于评估预后和为宫颈AC提供患者量身定制治疗的其他信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号